TRAIN study evaluated the efficacy and toxicity of weekly trastuzumab in combination with paclitaxel plus carboplatin as neoadjuvant treatment in patients with HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.